CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.
By Yan Jin, Z. Desta, V. Stearns, B. Ward, H. Ho, Kyung-Hoon Lee, T. Skaar, A. Storniolo, Lang Li, Adjei Araba and 9 more. Journal of the National Cancer Institute, 2005
971 citations recorded by the source corpus.
Subfields: Genetics, Pharmacology, Psychiatry and Mental health
View Paper: https://www.semanticscholar.org/paper/f94cdd3d284cf8442003fd713f0ea1cecad37f4c
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
In Pharmacology
- Shufeng Zhou
- C. Rodríguez‐Antona
- A. Gomez
- S. Sim
- Jun-Ping Liu
- B. Chowbay
- Magnus Ingelman-Sundberg
- W. Katon
In Psychiatry and Mental health
Citations in the corpus
- Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial (2013, background): “Lastly, if duloxetineandtamoxifenaretakentogether, duloxetine-induced CYP P450 2D6 enzyme inhibitioncould inhibit tamoxifen conversion to its active metabolite, endoxifen.(61,63,67,68) In conclusion, 5 weeks of duloxetine treatment was associated with a statistically and clinically significant impro”
- Polymorphism of human cytochrome P450 enzymes and its clinical impact (2009, background): “…*41 associated with impaired formation of antiestrogenic metabolites had significantly more recurrences of breast cancer and shorter relapse-free periods (Bijl et al., 2009a; Bonanni et al., 2006; Borges et al., 2006; Goetz et al., 2007; Goetz et al., 2005; Jin et al., 2005; Schroth et al., 2007).”
- Major depression after breast cancer: a review of epidemiology and treatment. (2008, background): “[203] found that CYP2D6 inhibiting SSRIs can lower the concentration of endoxifen, the active metabolite of tamoxifen.”
- Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine (2016, background): “Plasma level of endoxifen in UM patients is usually higher than that in PM and IM patients due to the presence of multiple functional CYP2D6 copies [53].”
- Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. (2007, background): “Endoxifen has about 100 times greater affinity for the estrogen receptor than tamoxifen (Jordan et al., 1977; Clarke et al., 2003; Jin et al., 2005) and tamoxifen-treated women homozygous for the defective allele CYP2D6⁎4 have been shown to have a worsened relapse-free time and disease-free…”
- American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline (2016, positive): “There is concern that SSRIs that inhibit the CYP2D6 (cytochrome P450 2D6) enzyme pathway, such as paroxetine, may reduce the conversion of tamoxifen to active metabolites, although a negative impact on breast cancer outcomes has not been conclusively demonstrated.(164) Consistent with recommendation”